Today: 17 May 2026
Lam Research stock price wobbles ahead of earnings as Wall Street braces for a big move
28 January 2026
1 min read

Lam Research stock price wobbles ahead of earnings as Wall Street braces for a big move

New York, Jan 28, 2026, 11:37 EST — Regular session

Lam Research shares slipped 0.1% to $238.15 by 11:37 a.m. EST, retreating from an early gain and edging toward session lows ahead of the chip equipment maker’s quarterly report scheduled after the bell.

The setup is straightforward but tense. Chip-tool makers are benefiting from a surge in AI-driven spending, yet their fate hinges on customer guidance about factory plans over the coming quarters.

Options traders are pricing in a big move. According to TipRanks, implied volatility suggests Lam’s stock could swing roughly 7.9% up or down after the earnings report, reflecting sharp expected market reactions.

Analysts surveyed by Seeking Alpha forecast Lam will report earnings of $1.17 per share on roughly $5.24 billion in revenue.

Lam will conduct its December 2025 earnings call this Wednesday at 2:00 p.m. Pacific, the company’s investor relations page shows.

Mizuho boosted its price target on Lam from $220 to $265 in a bullish note ahead of earnings. The broker projects wafer fab equipment (WFE) spending—the gear used to build and expand chip factories—will climb 13% in 2026 and 12% in 2027, describing the growth as a “significant acceleration.” TipRanks

Chip stocks have found support as the broader market pushes higher. The S&P 500 surpassed the 7,000 mark on Wednesday, buoyed by semiconductor gains ahead of the U.S. Federal Reserve’s rate decision, Reuters noted. “These big round numbers can be difficult psychological tests for the market,” said Jeff Buchbinder, chief equity strategist at LPL Financial. Reuters

Applied Materials climbed 1.2% in chip-equipment stocks, with KLA adding 0.3%. Meanwhile, ASML’s shares listed in the U.S. dipped 1.9%. The VanEck Semiconductor ETF moved higher by roughly 1.9%.

Investors are watching closely for shifts in tone on foundry and memory demand, the speed of new tool orders, and the split between Lam’s growth from recurring services versus new systems. Often, the guidance carries more weight than the quarter’s raw numbers.

The stock has hit the print with expectations already high. Even a slight sign of customers putting off factory spending, or pressure on margins, could quickly drag shares down — notably since the options market points to a potentially sharp move.

The company’s results arrive after the U.S. close on Jan. 28, with a keen focus on management’s outlook for the spending cycle through 2026.

Stock Market Today

  • Berkshire Hathaway CEO Greg Abel Revamps Portfolio with Major Stock Changes
    May 16, 2026, 7:29 PM EDT. Berkshire Hathaway, under new CEO Greg Abel, has significantly overhauled its equity portfolio in Q1, highlighted by a 224% increase in Alphabet shares, now Berkshire's seventh largest holding valued at $16.6 billion. Abel added Delta Air Lines and Macy's, while cutting multiple stocks, including a near-total sale of Constellation Brands and complete exit from Amazon shares. The largest reduction by value was in Chevron, cut by 35%, worth over $8 billion. The reshuffle marks a shift away from holdings linked to former portfolio manager Todd Combs, indicating a strategic realignment under Abel's leadership. Alphabet has gained 38% since the quarter ended.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Commvault stock steadies premarket after 31% wipeout on ARR worries
Previous Story

Commvault stock steadies premarket after 31% wipeout on ARR worries

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal
Next Story

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Go toTop